Bracco, ImaRx Pharma, Molecular Biosystems, Sonus regulatory update

The FDA postponed its scheduled June 30 advisory committee meeting to discuss SNUS's NDA to market EchoGen ultrasound contrast enhancing agent.

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE